PP
TLIS

PDT Partners’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

PDT Partners’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,326
Closed -$140K – 1153
2021
Q4 		$140K Buy
2,326
+319
+16% +$23.9K 0.01% 799
2021
Q3 		$188K Buy
+2,007
New +$267K 0.01% 700

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

PDT Partners's TLIS Position: Q1 2022 in Review

PDT Partners sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q1 2022, closing a stake of 2,326 shares — an estimated $140K sold.

PDT Partners first reported a position in TLIS in Q3 2021 and held it in 2 quarters. The position peaked at $188K in Q3 2021. 44 funds tracked by Wall St. Rank hold TLIS as of Q1 2022.

  • PDT Partners reported no remaining Talis Biomedical Corporation Common Stock position as of Q1 2022 after selling out during the quarter.
  • PDT Partners sold 2,326 Talis Biomedical Corporation Common Stock shares in Q1 2022, an estimated $140K.
  • PDT Partners first reported a position in Talis Biomedical Corporation Common Stock in Q3 2021 and held it in 2 quarters.
  • PDT Partners's Talis Biomedical Corporation Common Stock position peaked at $188K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.